bioRxivBiophysicsPreprint
Cooperativity and induced oligomerisation control the interaction of SARS- CoV-2 with its cellular receptor and patient-derived antibodies
R. Asor, A. Olerinyova, S. A. Burnap, M. S. Kushwah, F. Soltermann, L. P. Rudden, M. Hensen, S. Vasiljevic, J. Brun, M. Hill, L. Chang, W. Dejnirattisai, P. Supasa, J. Mongkolsapaya, D. Zhou, D. I. Stuart, G. Screaton, M. Degiacomi, N. Zitzmann, J. L. Benesch, W. B. Struwe, P. Kukura
Abstract
Viral entry is mediated by oligomeric proteins on the virus and cell surfaces. The association is therefore open to multivalent interactions between these proteins, yet such recognition is typically rationalised as affinity between monomeric equivalents. As a result, assessment of the thermodynamic mechanisms that control viral entry has been limited. Here, we use mass photometry to overcome the analytical challenges consequent to multivalency. Examining the interaction between the spike protein of SARS-CoV-2 and the ACE2 receptor, we find that ACE2 induces oligomerisation of spike in a variant-dependent fashion. We also demonstrate that patient-derived antibodies use induced-oligomerisation as a primary inhibition mechanism or to enhance the effects of receptor-site blocking. Our results reveal that naive affinity measurements are poor predictors of potency, and introduce a novel antibody-based inhibition mechanism for oligomeric targets. One-Sentence SummaryMultivalent interactions between viral proteins, cell-surface receptors, and anti-viral antibodies regulate infection and inhibition.
- organism: human
- assay: protein structure
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum
S. Fiedler, M. A. Piziorska, … T. P. J. Knowles·bioRxiv·Dec 20, 2020
- Antibody-mediated cell entry of SARS-CoV-2
M. G. Kibria, C. L. Lavine, … B. Chen·bioRxiv·Feb 20, 2023
- Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
I. Lui, X. X. Zhou, … J. A. Wells·bioRxiv·May 21, 2020
- Probing Affinity, Avidity, Anti-Cooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses
V. C. Yin, S.-H. Lai, … A. J. R. Heck·bioRxiv·Jun 18, 2021
- Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins
S. P. Anand, Y. Chen, … A. Finzi·bioRxiv·Sep 7, 2020
- Development and characterization of a multimeric recombinant protein based on the spike protein receptor binding domain of SARS-CoV-2 that can neutralize virus infection
V. A. de Lima, R. d. S. Ferreira, … S. Schenkman·bioRxiv·Feb 15, 2023